[1]
2016. Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients. Farmeconomia. Health Economics and Therapeutic Pathways. 17, 1 (Mar. 2016), 7–12. DOI:https://doi.org/10.7175/fe.v17i1.1225.